GHK-Cu Dosage in the Research Literature: Concentrations, Routes, and Half-Life

How GHK-Cu doses appear in the research record

GHK-Cu dosage in the research literature spans a wide range because the studies span cell culture, topical formulations and rodent systemic models — each with its own units. The point of this page is to report those doses faithfully and to frame them as what they are: experimental administrations, not guidance. The compliance footing is firm — there is no FDA- or EMA-approved therapeutic indication for GHK-Cu by any route; topical Copper Tripeptide-1 is a legal cosmetic ingredient, while injectable or oral systemic use is unapproved and research-only.

The lowest active concentrations are the in-vitro ones. In fibroblast culture, collagen synthesis began between 10^-12 and 10^-11 M and peaked near 10^-9 M ^[1]. Topical cosmetic and clinical formulations run far higher in nominal concentration, roughly 0.05% to 2% (w/w) in creams, serums and gels, because most of that material never reaches the dermis ^[3]. The two numbers are not contradictory; they describe different compartments — what the fibroblast responds to versus what is applied to the skin surface.

That compartment gap is the single most common source of confusion when reading GHK-Cu dose figures. A cell sitting in culture medium is bathed directly in the peptide; a fibroblast deep in the dermis receives only the fraction that survives the stratum corneum, the skin's enzymes, and dilution across tissue. So a 2% topical serum and a 10^-9 M culture dish are not competing claims about potency — they are measurements at opposite ends of a delivery chain. Reading any single concentration without asking which compartment it describes, and which form (free GHK or the copper chelate) was used, produces a number that looks precise but means little on its own.

Routes and doses studied across models

Rodent systemic studies used routes and doses that have no human equivalent and must not be read as such. Documented examples include mouse pulmonary emphysema at 0.2, 2 and 20 ug/g/day intraperitoneally on alternate days; mouse silicosis at 2 and 20 mg/kg; a mouse DSS-colitis model at 20 mg/kg by oral gavage ^[13]; and aging/cognition work at 15 mg/kg intranasally ^[6]. Rat behavioral studies used roughly 0.5 ug/kg to 0.5 mg/kg intraperitoneally ^[7].

The one controlled human dose in the record is topical: the ALAVAX 5-ALA-plus-GHK hair complex at 50 to 100 mg/mL applied to the scalp ^[4]. The routes catalogued across the literature include topical (cream, serum, liposome, nano-lipid carrier, ionic-liquid microemulsion, hydrogel dressing, nanofiber), intraperitoneal, intranasal, oral gavage, and intradermal microneedle delivery ^[6]. Injectable or systemic dosing protocols circulated in community contexts have no peer-reviewed human pharmacokinetic basis.

The route matters as much as the number, because GHK-Cu behaves very differently by compartment. Topically, the challenge is getting past the stratum corneum at all; systemically, the challenge is that the free peptide is cleared in minutes. This is why so much recent work is delivery-engineering rather than dose-finding — liposomal encapsulation, ionic-liquid microemulsions, palmitoylation and microneedle pretreatment are all attempts to put the same molecule where it can act, not to escalate how much is given ^[11]. A dose figure detached from its route and formulation tells you almost nothing about exposure at the target tissue.

Half-life and the pharmacokinetic gap

No rigorous human pharmacokinetic half-life has been published for GHK-Cu. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases; a rat HPLC study documented rapid metabolism of GHK to the dipeptide HK after intravenous dosing, and secondary literature cites a short systemic elimination half-life on the order of 1 to 2 hours, with the copper-chelated complex more stable than free GHK ^[6].

Topical behavior is the better-characterized half. Application forms a dermal copper depot — about 97 ug/cm^2 retained over 48 hours — which gives prolonged local availability even as systemic peptide is cleared quickly ^[10]. The honest summary: local persistence is documented, systemic human pharmacokinetics are not. That gap is the single most important thing to hold alongside any systemic dose figure.

Stability as a dosing variable

Dose is meaningless if the complex has degraded, so stability is itself a dosing variable. The GHK-Cu complex has a very high copper stability constant (log K about 16.4), far higher than free GHK, which limits pro-oxidant free-copper release; it is most stable near pH 5 to 6.5 at a 1:1 copper-to-peptide ratio ^[6]. The blue-violet color of a reconstituted solution is the expected Cu(II) absorption and indicates an intact complex; brown or green shifts indicate oxidation or precipitation. Strong reducing agents such as ascorbic acid below about pH 3.5 reduce Cu(II) and break the complex ^[6]. None of this is dosing advice — it is the chemistry that determines whether a stated concentration is still the molecule it claims to be.

There is also a delivery dimension to dose. Free GHK is highly hydrophilic (clogP -2.24), which limits passive penetration, so two products at the same labeled concentration can deliver very different amounts of active peptide depending on whether the formulation uses palmitoylation, liposomal encapsulation or a microemulsion to carry it across the skin barrier ^[11]. Concentration on a label and exposure at the target tissue are therefore loosely coupled at best. This is the recurring theme of the dosing literature: GHK-Cu's behavior is governed less by how much is present and more by what form it is in, what compartment it reaches, and whether the copper is still bound.